GlaxoSmithKline (LON:GSK) Earns “Reduce” Rating from Kepler Capital Markets

GlaxoSmithKline (LON:GSK)‘s stock had its “reduce” rating restated by research analysts at Kepler Capital Markets in a report issued on Monday, February 5th. They presently have a GBX 1,340 ($18.51) target price on the stock. Kepler Capital Markets’ price target would suggest a potential upside of 3.55% from the stock’s current price.

Several other equities analysts have also commented on the company. Barclays reaffirmed an “overweight” rating and set a GBX 1,650 ($22.80) target price on shares of GlaxoSmithKline in a report on Tuesday, January 30th. Jefferies Group reaffirmed a “buy” rating and set a GBX 1,500 ($20.72) target price on shares of GlaxoSmithKline in a report on Tuesday, January 16th. BNP Paribas reaffirmed a “neutral” rating and set a GBX 1,580 ($21.83) target price on shares of GlaxoSmithKline in a report on Tuesday, January 16th. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,760 ($24.32) target price on shares of GlaxoSmithKline in a report on Monday, January 15th. Finally, Deutsche Bank upped their target price on GlaxoSmithKline from GBX 1,380 ($19.07) to GBX 1,440 ($19.89) and gave the company a “hold” rating in a report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of GBX 1,540.45 ($21.28).

GlaxoSmithKline (LON GSK) opened at GBX 1,294 ($17.88) on Monday. The company has a market capitalization of $64,160.00 and a P/E ratio of 4,174.19. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.07) and a fifty-two week high of GBX 1,724.50 ($23.83).

In related news, insider Sir Roy Anderson acquired 562 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was bought at an average price of GBX 1,278 ($17.66) per share, for a total transaction of £7,182.36 ($9,923.13). Also, insider Patrick Vallance sold 20,000 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.10), for a total value of £262,000 ($361,978.45). Insiders have bought a total of 590 shares of company stock valued at $754,966 in the last quarter.

WARNING: “GlaxoSmithKline (LON:GSK) Earns “Reduce” Rating from Kepler Capital Markets” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/13/glaxosmithklines-gsk-reduce-rating-reaffirmed-at-kepler-capital-markets.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply